-+ 0.00%
-+ 0.00%
-+ 0.00%
GlaxoSmithKline: The AZUR-1 trial reached the primary end, achieving meaningful continuous clinical complete remission at 12 months.
Share
Listen to the news
GlaxoSmithKline: The AZUR-1 trial reached the primary end, achieving meaningful continuous clinical complete remission at 12 months.
Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.
What's Trending